Table 1.
Results of in vitro azole susceptibility testing and 16 ERG11 sequence type analysis for 164 clinical isolates of Candida guilliermondii.
| Sequence type | No. | % | No. (%) of non-WT isolates | Non-synonymous mutations of ERG11 | |
|---|---|---|---|---|---|
| Fluconazole | Voriconazole | ||||
| 1 | 65 | 39.6 | 1 (1.5) | 1 (1.5) | Reference sequence |
| 2 | 45 | 27.4 | 0 (0) | 0 (0) | W37C |
| 3 | 25 | 15.2 | 0 (0) | 0 (0) | P518R |
| 4 | 6 | 3.7 | 0 (0) | 0 (0) | P430Q |
| 5 | 3 | 1.8 | 0 (0) | 0 (0) | D492N, P518R |
| 6 | 1 | 0.6 | 0 (0) | 0 (0) | W37C, P518R |
| 7 | 1 | 0.6 | 0 (0) | 0 (0) | Y41F, L328T, S346T, V410M, S420T, N485K |
| 8 | 3 | 1.8 | 1 (33.3) | 3 (100) | Y41F, L328T, S346T, V410M, S420T |
| 9 | 4 | 2.4 | 4 (100) | 4 (100) | Y41F, Y132F, L328T, S346T, V410M, S420T |
| 10 | 1 | 0.6 | 1 (100) | 1 (100) | G16S, Y41F, Y132F, M332I, S346T, S420T |
| 11 | 2 | 1.2 | 0 (0) | 0 (0) | G16S, F39L, R247K, L328I, S346T, S420T |
| 12 | 2 | 1.2 | 2 (100) | 2 (100) | Y41F, L328T, S346T, V410M, S420T, G459S |
| 13 | 2 | 1.2 | 2 (100) | 2 (100) | Y132F |
| 14 | 2 | 1.2 | 2 (100) | 2 (100) | K143R, P518R |
| 15 | 1 | 0.6 | 1 (100) | 1 (100) | Q469K |
| 16 | 1 | 0.6 | 1 (100) | 1 (100) | I303V |
| Total | 164 | 100 | 15 (9.1) | 17 (10.4) | |